




WORLD HEALTH ORGANIZATION

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

MODELS, MECHANISMS AND ETIOLOGY OF TUMOUR PROMOTION



EDITORS: M. BÖRZSÖNYI, N.E. DAY, K. LAPIS & H. YAMASAKI

LYON 1984

IARC SCIENTIFIC PUBLICATIONS No. 56

WORLD HEALTH ORGANIZATION



INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

MODELS, MECHANISMS AND ETIOLOGY OF TUMOUR PROMOTION

Proceedings of a Symposium organized by
the Hungarian Cancer Society and the IARC,
held in Budapest,

16–18 May 1983

EDITORS

M.BÖRZSÖNYI
N.E. DAY

K. LAPIS
H. YAMASAKI

IARC Scientific Publications No. 56

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
LYON
1984

The International Agency for Research on Cancer (IARC) was established in 1965 by the World Health Assembly, as an independently financed organization within the framework of the World Health Organization. The headquarters of the Agency are at Lyon, France.

The Agency conducts a programme of research concentrating particularly on the epidemiology of cancer and the study of potential carcinogens in the human environment. Its field studies are supplemented by biological and chemical research carried out in the Agency's laboratories in Lyon and, through collaborative research agreements, in national research institutions in many countries. The Agency also conducts a programme for the education and training of personnel for cancer research.

The publications of the Agency are intended to contribute to the dissemination of authoritative information on different aspects of cancer research.

Oxford University Press, Walton Street, Oxford OX2 6DP

London New York Toronto
Delhi Bombay Calcutta Madras Karachi
Kuala Lumpur Singapore Hong Kong Tokyo
Nairobi Dar es Salaam Cape Town
Melbourne Auckland

and associated companies in
Beirut Berlin Ibadan Mexico City Nicosia

Oxford is a trade mark of Oxford University Press

Published in the United States
by Oxford University Press, New York

ISBN 0 19 723058 X
ISBN 92 832 1156 1 (Publisher)
© International Agency for Research on Cancer 1984

The authors alone are responsible for the views expressed in the signed articles in this publication.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press

PRINTED IN SWITZERLAND

FOREWORD

Both epidemiological and laboratory studies indicate that most malignant tumours result from the interaction of target cells with multiple endogenous and exogenous factors and that their development is the result of a succession of steps occurring over a considerable part of the host's life span. Environmental factors are considered to play major roles at different stages during the development of human cancers.

One of the main goals of the research activities of the Agency is the primary prevention of human cancer, and the identification of environmental risk factors in carcinogenesis is an important aspect. In order to fulfill this goal, it is also essential to understand the mechanisms underlying different stages of carcinogenesis. Mechanisms of later stages of carcinogenesis – especially tumour promotion in two-stage models of carcinogenesis – are now being studied widely; however, much less is known about the later stages than about the earlier stage of carcinogenesis – including tumour initiation.

This volume is the first IARC publication devoted specifically to multi-stage carcinogenesis. It is my hope that it will not only summarize the state of present knowledge but also encourage further investigations for a better understanding of tumour promotion and multi-stage carcinogenesis.

The hospitality of the Hungarian Cancer Society, Budapest, is gratefully acknowledged. The meeting was cosponsored by the European Association for Cancer Research and was financed in part by donations made by a number of individual firms in the Federal Republic of Germany, France, Hungary, Italy, Switzerland, the UK and the USA.

L. Tomatis, MD
Director
International Agency for Research
on Cancer

INTRODUCTION

Following the first observation of two-stage carcinogenesis on mouse skin in the 1940s, many studies of tumour promotion were carried out, with mouse skin as the target organ and with phorbol esters as model tumour promoters. More recently, work with other species, at other sites and with other agents has led to acceptance that the multi-stage process is a general mechanism of carcinogenesis. In parallel, but almost independently, multi-stage models have been developed to explain a wide variety of epidemiological observations. An abundance of data has accumulated, both epidemiological and experimental, in support of the idea that the development of many cancers is multi-stage.

In order to understand the nature of the multi-stage process of carcinogenesis, and to identify risk factors involved in the causation of cancer, multi-disciplinary approaches are essential. However, epidemiologists and laboratory investigators often take separate and independent approaches to the very same problem. In the study of tumour promotion, cooperation between experimentalists and epidemiologists is especially desirable, since the elimination of risk factors that act in the later stages of carcinogenesis should lead to rapid reductions in human cancer mortality.

The present symposium was planned to stimulate a dialogue between epidemiologists and experimentalists in order to advance our knowledge of multi-stage carcinogenesis. Thus, this volume contains descriptions of human models of multi-stage carcinogenesis and models for possible identification of etiological factors in terms of multi-stage or multi-factorial carcinogenesis, as well as models and cellular and molecular mechanisms of experimental tumour promotion.

The interaction of epidemiologists and laboratory experimentalists in studies of the mechanism of multi-stage carcinogenesis and in the identification of environmental risk factors in terms of multi-stage carcinogenesis is still in an initial phase. It is our sincere hope that this volume will stimulate more such interaction in order to attain our mutual goal – cancer prevention.

The Editors

PARTICIPANTS

E. Amtmann
Institute of Virus Research,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

C.L. Ashendel
McArdle Laboratory for Cancer
Research, University of Wisconsin,
Madison, WI 53706, USA

S. Bardócz
Department of Biochemistry,
University Medical School,
4012 Debrecen, Hungary

G. Bauer
Institute of Virology, University of
Freiburg, Hermann-Herder Strasse 11,
78 Freiburg, FRG

C.S. Baxter
Department of Environmental Health
University of Cincinnati, 3223 Eden
Avenue, Cincinnati, OH 45267, USA

A. Bisshop
Laboratory for Carcinogenesis and
Mutagenesis, National Institute of
Public Health, 3720 BA Bilthoven,
The Netherlands

P.M. Blumberg
Laboratory of Cellular Carcino-
genesis and Tumor Promotion,
National Cancer Institute, Bethesda,
MD 20205, USA

M. Boeva
Institute of Oncology, Medical
Academy, Sofia, Bulgaria

F. Boján
Department of Hygiene, University
Medical School, 4012 Debrecen,
Hungary

M. Börzsönyi
National Institute of Hygiene
Gyáli út 2-6, 1966 Budapest, Hungary

R.K. Boutwell
McArdle Laboratory, University of
Wisconsin, Madison, WI 53706, USA

A. Buchmann
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

R.D. Bulbrook
Imperial Cancer Research Fund,
Lincoln's Inn Fields, London
WC2A 3PX, UK

B.I. Carr
Department of Medicine, City of Hope
Medical Center, 1500 East Duarte
Road, Duarte, CA 91010, USA

S.M. Cohen
Pathology and Laboratory Medicine
Department, University of Nebraska
Medical Center, Omaha, NE, USA

N.H. Colburn
Laboratory of Viral Carcinogenesis,
National Cancer Institute, Bldg.
560, Room 12-89, Frederick,
MD 21701, USA

PARTICIPANTS

M. Collins
Imperial Cancer Research Fund,
Lincoln's Inn Fields, London
WC2A 3PX, UK

O. Csuka
Research Institute of Oncopathology,
Ráth Gy.u.7., 1122 Budapest, Hungary

N.E. Day
Unit of Biostatistics, International
Agency for Research on Cancer,
150 cours Albert Thomas, 69372 Lyon,
Cédex 08, France

W. Davis
Research Training and Liaison Unit,
International Agency for Research on
Cancer, 150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

C. Delescluse
International Centre for
Dermatological Research, Sophia
Antipolis, 06565 Valbonne, France

E. Deml
Department of Toxicology, Institute
of Toxicology and Biochemistry,
Society of Radiation and
Environmental Research,
8042 Neuherberg, FRG

T.A. Dragani
Division of Experimental Oncology A,
National Tumour Institute, Via G.
Venezian 1, 20133 Milan, Italy

P.E. Driedger
LC Services Corporation, 165 New
Boston Street, Woburn, MA 01801,
USA

S. Eckhardt
National Institute of Oncology, Ráth
Gy.u. 7., 1122 Budapest, Hungary

L. Eliasson
Department of Tumor Biology,
Karolinska Institutet, 104 01
Stockholm, Sweden

J.M. Elwood
Department of Community Health,
University of Nottingham, Queen's
Medical Centre, Clifton Boulevard,
Nottingham, NG7 2UH, UK

T. Enomoto
Division of Environmental Carcino-
genesis, International Agency for
Research on Cancer,
150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

P. Fabian
Neustadt, FRG

G. Fürstenberger
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

H.St C. Gainer
Paterson Laboratories, Christie
Hospital and Holt Radium Institute,
Manchester M20 9BX, UK

D. Gerns
Pharmacology, Medical School of
Hanover, Hanover, FRG

H. Greim
Department of Toxicology,
Society of Radiation and
Environmental Research, 8042
Neuherberg, FRG

PARTICIPANTS

M. Gschwendt
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

E. Hamel
International Agency for Research on
Cancer, 150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

E. Hecker
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

M. Hergenbahn
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

E. Heseltine
Editorial and Publications Services,
International Agency for Research on
Cancer, 150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

Y. Hiasa
First Department of Pathology, Nara
Medical University, Kashihara-shi,
Nara 634, Japan

E. Hidvégi
Frédéric Joliot-Curie National
Research Institute for Radiobiology
and Radiohygiene, Pentz K.u. 5.,
1775 Budapest, Hungary

K.H. Horn
Department of Chemical
Carcinogenicity, Central Institute
of Cancer Research Berlin-Buch,
Lindenberger Weg 80,
1115 Berlin-Buch, GDR

N. Ito
Department of Pathology, Nagoya City
University Medical School,
Nagoya 467, Japan

L. Juhász
Cancer Registry of
Szabolcs-Szatmár County,
4401 Nyiregyháza,
Hungary

S. Kimura
Department of Food Chemistry,
Tohoku University, 1-1 Tsutsumidori
Amamiyacho, Sendai, Japan

A.R. Kinsella
Paterson Laboratories, Christie
Hospital and Holt Radium Institute,
Manchester M20 9BX, UK

V. Kinzel
Institute of Experimental Pathology,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

A.J.P. Klein-Szántó
The University of Texas System
Cancer Center, Science Park Research
Division, Smithville, TX 78957, USA

L. Komáromy
Department of Biology, University
Medical School, 7643 Pécs, Hungary

Y. Konishi
Department of Oncological Pathology,
Cancer Center, Nara Medical College,
840 Shijo-cho, Kashihara, Nara 634,
Japan

M. Kramer
Hoechst AG, Pharma Forschung
Toxikologie, 6230 Frankfurt/Main 80,
FRG

PARTICIPANTS

T. Kubasova
Frédéric Joliot-Curie National
Research Institute for Radiobiology
and Radiohygiene, Pentz K.u. 5.,
1775 Budapest, Hungary

H.W. Kunz
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

M. Lafaurie
Laboratoire d'Histologie, INSERM
U210, UER Médecine, 06034 Nice,
France

K. Lapis
First Institute of Pathology and
Experimental Cancer Research,
Semmelweis Medical University,
1085 Budapest, Hungary

C. Lasne
Institute for Scientific Research on
Cancer, 94802 Villejuif, France

A. Likhachev
Unit of Mechanisms of Carcino-
genesis, International Agency for
Research on Cancer,
150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

F. Marks
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

E. Matsunaga
Department of Human Genetics,
National Institute of Genetics,
Mishima, Shizuoka-ken, 411, Japan

F.M. Michiels
LRACC, Institute for Scientific
Research on Cancer, 94802 Villejuif,
France

A.W. Murray
School of Biological Sciences,
Flinders University, South
Australia, 5042

Y. Moulé
Institute for Scientific Research on
Cancer, 7 rue Guy Moquet,
94802 Villejuif, France

P. Nettesheim
National Institute of Environmental
Health Sciences, Research Triangle
Park, NC 27709, USA

H.-G. Neumann
Institute of Pharmacology and
Toxicology, University of Würzburg,
Versbacher Strasse 9, 8700 Würzburg,
FRG

D. Oesterle
Department of Toxicology, Institute
of Toxicology and Biochemistry,
Society of Radiation and
Environmental Research,
8042 Neuherberg, FRG

A.F. Pelfrene
Rhône-Poulence Agrochimie, 14-20 rue
Pierre Baizet, 69263 Lyon, France

C. Peraino
Division of Biological and Medical
Research, Argonne National
Laboratory, Argonne, IL 60439, USA

M. Petkova
Governmental Hospital, 1199 Sofia,
Bulgaria

PARTICIPANTS

J. Peto
Institute of Cancer Research,
Division of Epidemiology,
Clifton Avenue, Sutton,
Surrey SM2 5PX, UK

V.G. Pinchouk
Cytology and Virology Departments,
Institute for Oncology Problems,
Kiev, USSR

A. Pintér
National Institute of Hygiene, Gyáli
út 2–6, 1966 Budapest, Hungary

M. Poirier
Bldg. 37, Room 3A23, National Cancer
Institute, Bethesda, MD 20205, USA

J. Pot-Deprun
Institute for Scientific Research on
Cancer, 94802 Villejuif, France

L. Pylev
Cancer Research Center, Academy of
Medical Sciences, Moscow 115478,
USSR

P. Rády
Department of Biochemistry,
University Medical School,
4012 Debrecen, Hungary

G. Ragnotti
General Pathology, Faculty of
Medicine, University of Brescia,
25100 Brescia, Italy

M. Reinacher
Veterinary-Pathology Institute
Frankfurter Strasse 96,
6300 Giessen, FRG

E. Rivedal
Laboratory for Environmental and
Occupational Cancer, Norwegian
Radium Hospital, Montebello, Oslo 3,
Norway

H. Roeser
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

T. Sanner
Laboratory for Environmental and
Occupational Cancer, Norwegian
Radium Hospital, Montebello, Oslo 3,
Norway

E. Scherer
Division of Chemical Carcinogenesis,
Antoni Van Leeuwenhoek-Huis,
The Netherlands Cancer Institute,
121 Plesmanlaan, 1066 CX Amsterdam,
The Netherlands

R. Schmidt
Institute of Biochemistry,
German Cancer Research Center,
6900 Heidelberg, FRG

M. Schönfelder
Surgical Clinic of the
Karl-Marx University, Liebigstrasse 20,
7010 Leipzig, GDR

R. Schulte-Hermann
Institute of Toxicology and
Pharmacology of the
Philipps University Marburg,
Pilgrimstein 2, 355 Marburg, FRG

M. Schwarz
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

J. Schweizer
Institute of Experimental Pathology,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

PARTICIPANTS

J. Sugár
Research Institute of Oncopathology,
Ráth Gy.u. 7., 1122 Budapest,
Hungary

G. Sydow
Central Institute of Cancer Research,
Academy of Sciences of the GDR,
1115 Berlin-Buch, GDR

S. Szondy
Department of Biochemistry,
University Medical School,
4012 Debrecen, Hungary

S.-W. Teigen
The State Pollution Control
Authority, P.O. Box 8100 Dep., Oslo 1,
Norway

H.A. Tennekes
Institute of Biochemistry,
German Cancer Research Center,
Im Neuenheimer Feld 280,
6900 Heidelberg, FRG

E.B. Thorling
The Institute of Cancer Research,
Radium Stationen, Nørrebrogade 44,
8000 Aarhus C, Denmark

A. Tompa
National Institute of Occupational
Health, Nagyvárad tér 2.,
1096 Budapest, Hungary

A. Tigyí
Department of Biology, University
Medical School, 7643 Pécs, Hungary

G. Török
National Institute of Hygiene, Gyáli
út 2-6, 1966 Budapest, Hungary

J.E. Trosko
Department of Pediatrics/Human
Development, Michigan State
University, East Lansing, MI 48824,
USA

V. Turusov
Cancer Research Center, Academy of
Medical Sciences, Moscow 115478,
USSR

F. Waechter
Ciba-Geigy Limited, 4002 Basel,
Switzerland

I.B. Weinstein
College of Physicians and Surgeons,
Columbia University, New York,
NY 10032, USA

U. Willnow
Clinic for Children's Surgery of the
Karl-Marx University, Liebigstrasse 32,
7010 Leipzig, GDR

I.P. Witz
Department of Microbiology, The
George S. Wise Faculty of Life
Sciences, Tel Aviv University,
Ramat Aviv 69978, Israel

V. Wunderlich
Central Institute of Cancer Research,
Academy of Sciences of the GDR,
1115 Berlin-Buch, GDR

H. Yamasaki
International Agency for Research on
Cancer, 150 cours Albert Thomas,
69372 Lyon, Cédex 08, France

S.H. Yuspa
National Cancer Institute, Bethesda,
MD 20205, USA

TABLE OF CONTENTS

Foreword	
L. Tomatis.....	vii
Introduction	
The Editors.....	ix
List of Participants.....	xi

MODELS AND MECHANISMS OF SKIN TUMOUR PROMOTION

On the role of tumour promotion in chemical carcinogenesis	
R.K. Boutwell.....	3
Stages of tumour promotion in skin	
F. Marks & G. Fürstenberger.....	13

MODELS AND MECHANISMS OF LIVER TUMOUR PROMOTION

Alterations of markers during hepatocarcinogenesis in rats	
K. Lapis, E. Ujhelyi, M. Gyenes & A. Jeney.....	25
Relationship of histochemically detectable altered hepatocyte foci to hepatic tumorigenesis	
C. Peraino, E.F. Staffeldt, B.A. Carnes, V.A. Ludeman, J.A. Blomquist & S.D. Vesselinovitch.....	37
Initiation-promotion-initiation. Induction of neoplastic foci within islands of precancerous liver cells in the rat	
E. Scherer, A.W. Feringa & P. Emmelot.....	57
Aberrant expression of adaptation to phenobarbital may cause selective growth of foci of altered cells in rat liver	
R. Schulte-Hermann, I. Timmermann-Trosiener & J. Schuppler.....	67
Promoting effect of phenobarbital on <i>N</i> -bis(2-hydroxypropyl)nitrosamine thyroid tumorigenesis in rats. Effect of varying duration of exposure to phenobarbital	
Y. Hiasa, Y. Kitahori, N. Konishi, N. Enoki & T. Fujita.....	77
The mechanism of cocarcinogenic action of ethanol in rat liver	
M. Schwarz, A. Buchmann, M. Moore & W. Kunz.....	83

TUMOUR PROMOTION IN OTHER ORGANS

Urinary bladder carcinogenesis S.M. Cohen, R. Hasegawa, R.E. Greenfield & L.B. Ellwein.....	93
Studies on the action of tumour promoters and antipromoters on respiratory-tract epithelium P. Nettesheim, J.C. Barrett, M.J. Mass, V.E. Steele & T.E. Gray.....	109
The effect of promoters on 1,2-dimethylhydrazine-induced colon carcinogenesis O. Csuka, Z. Szentirmay & J. Sugár.....	129

MEMBRANE INTERACTION OF TUMOUR-PROMOTING AGENTS

Analysis of membrane and cytosolic phorbol ester receptors P.M. Blumberg, B. König, N.A. Sharkey, K.L. Leach, S. Jaken & A.Y. Jeng.....	139
A phorbol ester-binding inhibitory factor from human placenta. Partial purification, characterization and biological effects E. Hamel, H. Yamasaki & J.L. Tayot.....	157
Specific lipid components in membrane receptors of 12- <i>O</i> -tetradecanoylphorbol-13-acetate as revealed by direct photoaffinity labelling M. Hergenhahn & E. Hecker.....	165
Membrane-mediated responses to 12- <i>O</i> -tetradecanoylphorbol-13-acetate in human skin fibroblasts A.R. Kinsella, A.D. Whetton, E. de Wynter, G.W. Bazill, C.M. Heyworth & M.D. Houslay.....	177

CELLULAR RESPONSE TO TUMOUR-PROMOTING AGENTS

Mechanisms of initiation and promotion in mouse epidermis S.H. Yuspa.....	192
Role of specific membrane and genetic changes in the mechanism of tumour promotion. Studies with promoter-resistant variants N.H. Colburn, L. Srinivas, G.A. Hegamyer, L.D. Dion, E.J. Wendel, M. Cohen & T.D. Gindhart.....	205
Intercellular communication, cell differentiation and tumour promotion H. Yamasaki, T. Enomoto & N. Martel.....	217
The use of in-vitro assays to study and to detect tumour promoters J.E. Trosko, C. Jone & C.C. Chang.....	239
Interaction of phorbol derivatives with replicating cells V. Kinzel, G. Fürstenberger, J. Richards, K. Goerttler, H. Loehrke & F. Marks.....	253
Effect of 12- <i>O</i> -tetradecanoylphorbol-13-acetate on selection of drug-resistant phenotypes in rodent cells F. Bojan, A.R. Kinsella & M. Fox.....	265

INTERACTION OF TUMOUR PROMOTERS WITH HOST GENES, VIRUSES AND THE IMMUNE SYSTEM

Initial cellular targets and eventual genomic changes in multistage carcinogenesis	
I.B. Weinstein, S. Gattoni-Celli, P. Kirschmeier, M. Lambert, W. Hsiao, J. Backer & A. Jeffrey.....	277
Enhancement of primate retrovirus synthesis by tumour promoters	
V. Wunderlich, G. Sydow & L. Baumbach.....	299
Interaction of tumour-promoting agents with immunofunctional cells <i>in vitro</i> and <i>in vivo</i>	
C.S. Baxter, R.A. Schoof & A.T. Lawrence.....	305
Stimulation of macrophage activity by 12- <i>O</i> -tetradecanoylphorbol-13-acetate	
D. Gerns, U. Staar, W. Grimm, G. Hausmann, C.F. Körner, K. Resch & P.H. Krammer.....	319

MODELS OF MULTI-STAGE CARCINOGENESIS IN EPIDEMIOLOGY

Epidemiological data and multistage carcinogenesis	
N.E. Day.....	339
Early- and late-stage carcinogenesis in mouse skin and in man	
J. Peto.....	359
Multistage and multifactorial carcinogenesis in hereditary tumours, with special reference to retinoblastoma	
E. Matsunaga.....	373
Oestrogens and the etiology and clinical course of breast cancer	
R.D. Bulbrook, J.W. Moore, D.Y. Wang & G.M.G. Clark.....	385

EXPERIMENTAL MODELS TO STUDY ETIOLOGICAL FACTORS IN MULTI-STAGE CARCINOGENESIS

Drugs, food additives and natural products as promoters in rat urinary bladder carcinogenesis	
N. Ito, S. Fukushima, T. Shirai, A. Hagiwara & K. Imaida.....	399
5-Azacytidine. Promoting activity for rat hepatocellular carcinoma	
B.I. Carr, J.G. Reilly & A.D. Riggs.....	409
Influence of ethyl alcohol on carcinogenesis induced with <i>N</i> -nitrosodiethylamine	
L. Griciūte, M. Castegnaro & J.-C. Béréziat.....	413

ETIOLOGY OF HUMAN MULTI-STAGE CARCINOGENESIS

Initiation and promotion actions of ultraviolet radiation on malignant melanoma	
J.M. Elwood.....	421

Cocarcinogens of the tumour-promoter type as potential risk factors of cancer in man. A first complete experimental analysis of an etiological model situation and some of its consequences	
E. Hecker.....	441
Agriculturally-related carcinogenic risk	
M. Börzsönyi, G. Török, A. Pintér & A. Surján.....	465
Drugs and environmental chemicals as promoters	
H. Greim, E. Deml & D. Oesterle.....	487

INHIBITION OF TUMOUR PROMOTION

Can tumour promotion be effectively inhibited?	
T.J. Slaga.....	497

CONCLUDING REMARKS

Concluding remarks and future perspectives	
E. Hecker.....	509

AUTHOR INDEX.....	523
-------------------	-----

SUBJECT INDEX.....	525
--------------------	-----

**MODELS AND MECHANISMS
OF SKIN TUMOUR PROMOTION**

